Pfizer’s Antithrombotic Fragmin Recommended For Use In Cancer Patients

FDA's Oncologic Drugs Advisory Committee unanimously recommended approval of an sNDA for Pfizer's low molecular weight heparin Fragmin for treatment and prevention of venous thromboembolism in cancer patients